TAG:
genetic testing
Genetic Tests Grow in Number, Complexity
By Robert Michel | From the Volume XXVIII, No. 10 – July 26, 2021 Issue
CEO SUMMARY: Getting paid for genetic tests continues to be a challenge. This is true for both payers and the labs that perform the tests. Even physicians are dissatisfied with the status quo because they must deal with patients unhappy about the high cost of genetic tests. The prob…
How to Achieve Success with Genetic Test Prior Authorization
By Robert Michel | From the Volume XXVIII, No. 10 – July 26, 2021 Issue
AS MANAGED CARE PAYERS INCREASINGLY REQUIRE PRIOR AUTHORIZATION FOC GENETIC TESTS, clinical laboratories should understand the ins and outs of what it takes to get reimbursed for testing they provide. Almost all payers now require prior authorization (P…
New Year Brings Three New Clinical Lab Trends
By Robert Michel | From the Volume XXVIII No. 3 – March 1, 2021 Issue
CEO SUMMARY: Since the year began, three trends have affected clinical laboratories and anatomic pathology groups. First is a continuing surge in COVID-19 test volume. Second is inconsistent payment from government and commercial insurers for SARS-CoV-2 test claims. Third is growing…
DOJ Delivers $6B Lab Fraud Crackdown
By Mary Van Doren | From the Volume XXVII, No. 14 – October 5, 2020 Issue
This is an excerpt of a 1,028-word article in the October 5, 2020 issue of THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: In this latest lab fraud crackdown, Department of Justice cases involving clinical labs or molecular te…
Medicare Pays 500% More for Molecular Test Claims
By Robert Michel | From the Volume XXVII, No. 14 – October 5, 2020 Issue
CEO SUMMARY: Rapid growth in what Medicare spent for molecular tests in recent years may lead federal investigators to increase scrutiny of fraudulent billing for clinical laboratory and molecular pathology tests, according to a lab consultant who has tracked such spending in recent y…
DOJ $6B Fraud Crackdown Charges 345 Defendants
By Robert Michel | From the Volume XXVII, No. 14 – October 5, 2020 Issue
CEO SUMMARY: Department of Justice cases involving clinical labs or molecular test claims may represent about half (or about $3 billion) of the total fraudulent claims. Those claims stem from genetic testing, urine-drug and other tests, and healthcare services, the DOJ said. In additi…
Veritas Genetics to Close Its Testing Operations in U.S.
By Joseph Burns
MAYBE CHARGING CONSUMERS THE LOW PRICE of $599 for a whole human genome sequence is not a winning financial strategy. That’s one possible reason why closely-watched Veritas Genetics of Cambridge, Mass., will stop operations in the United States. It was in July that Veritas annou…
Labs May Be Excluded from Revised Stark, AKS Rules
By Joseph Burns | From the Volume XXVII No. 1 – January 6, 2020 Issue
CEO SUMMARY: When CMS and the OIG issued proposed rules last fall to make it easier for providers to participate in value-based and coordinated care arrangements, they considered excluding clinical labs, pharma companies, and DME firms because of concerns that the proposed rules could pro…
Labs May Be Excluded from Revised Stark Law, AKS Rules
This is an excerpt of a 1,460-word article in the Jan. 6, 2020 issue of THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: Here are early insights about a federal compliance reform that has not gotten much attention among clinical la…
Lab Benefit Managers Want to Help Health Plans
By Joseph Burns
CEO SUMMARY: Laboratory benefit management companies that offer a range of services to health insurers are gaining influence over clinical lab testing in important ways. On behalf of health insurers, LBMs will select labs for a payer’s network, then manage that network. They also manage…
CURRENT ISSUE

Volume XXXII, No. 8 – June 2, 2025
The leveraging of data is very important for creating laboratory and healthcare efficiencies. In an exclusive interview with The Dark Report, Bradley Bostic, founder, chair, and CEO of healthcare and laboratory data intelligence Company HC1, discusses trends in healthcare, how to position clinical laboratories as a strategic asset, and ways to analyze diagnostic data to improve efficiency and increase the bottom line.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized